Literature DB >> 31134487

Role of Apolipoprotein E, Cathepsin D, and Brain-Derived Neurotrophic Factor in Parkinson's Disease: A Study from Eastern India.

Prosenjit Pal1, Tamal Sadhukhan1, Subhadip Chakraborty1, Sriparna Sadhukhan1, Arindam Biswas1, Shyamal K Das2, Kunal Ray3, Jharna Ray4.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease with complex etiology. Both genetic and environmental factors play significant role. Apart from candidate genes, some modifier genes have been reported to be associated with the altered risk of PD. Previous studies have identified Apolipoprotein E (APOE), Cathepsin D (CTSD), and Brain-Derived Neurotrophic Factor (BDNF) as key players of neurodegenerative pathways with their variants associated with different neurodegenerative diseases. Hence, this study aims to identify the potential role of these modifier genes in the pathogenesis of PD among Eastern Indian PD patients. A case-control study was performed using 302 clinically diagnosed PD patients and 304 ethnically matched controls. Promoter SNPs of APOE (rs449647, rs405509) and BDNF (rs56164415), and coding SNPs of APOE (rs429358, rs7412 resulting in ε2, ε3, and ε4 alleles), CTSD (rs17571), and BDNF (rs6265) were analyzed by PCR-RFLP and bidirectional sequencing. The effect of rs56164415 on BDNF expression was characterized by Luciferase assay. APOEε4 allele was significantly overrepresented (p value = 0.0003) among PD patients, whereas ε3 allele was predominant in the control population. The promoter haplotype (A-rs449647, G-rs405509) of APOE was preponderant among female PD patients posing risk. No association was found for CTSD polymorphism. The 'T/T' genotype of BDNF rs56164415 was overrepresented (p-value = 0.02) among early onset PD patients. Expression of BDNF for the 'T/T' variant was significantly lower (p-value = 0.012) than the 'C/C' variant, suggesting a possible role in PD pathogenesis. This study suggests that APOE and BDNF may serve as modifier loci among eastern Indian PD patients.

Entities:  

Keywords:  APOE; BDNF; CTSD; Luciferase assay; Parkinson’s disease

Mesh:

Substances:

Year:  2019        PMID: 31134487     DOI: 10.1007/s12017-019-08548-4

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  35 in total

1.  Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Authors:  Y Davidson; L Gibbons; A Pritchard; J Hardicre; J Wren; J Tian; J Shi; C Stopford; C Julien; J Thompson; A Payton; U Thaker; A J Hayes; T Iwatsubo; S M Pickering-Brown; N Pendleton; M A Horan; A Burns; N Purandare; C L Lendon; D Neary; J S Snowden; D M A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

2.  Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra.

Authors:  K Parain; M G Murer; Q Yan; B Faucheux; Y Agid; E Hirsch; R Raisman-Vozari
Journal:  Neuroreport       Date:  1999-02-25       Impact factor: 1.837

3.  The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson's disease: a meta-analysis.

Authors:  Elias Zintzaras; Georgios M Hadjigeorgiou
Journal:  J Hum Genet       Date:  2005-09-20       Impact factor: 3.172

4.  Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.

Authors:  D W Howells; M J Porritt; J Y Wong; P E Batchelor; R Kalnins; A J Hughes; G A Donnan
Journal:  Exp Neurol       Date:  2000-11       Impact factor: 5.330

5.  Meta-analysis of the association of the cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer's disease: a HuGE gene-disease association review.

Authors:  Christos Ntais; Anastasia Polycarpou; John P A Ioannidis
Journal:  Am J Epidemiol       Date:  2004-03-15       Impact factor: 4.897

6.  The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.

Authors:  Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582

7.  The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease.

Authors:  J-C Lambert; N Coyle; C Lendon
Journal:  J Med Genet       Date:  2004-02       Impact factor: 6.318

8.  Risk of Parkinson disease in women: effect of reproductive characteristics.

Authors:  P Ragonese; M D'Amelio; G Salemi; P Aridon; M Gammino; A Epifanio; L Morgante; G Savettieri
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

9.  Modulation of disease risk according to a cathepsin D / apolipoprotein E genotype in Parkinson's disease.

Authors:  T Schulte; S Böhringer; L Schöls; T Müller; C Fischer; O Riess; H Przuntek; K Berger; J T Epplen; R Krüger
Journal:  J Neural Transm (Vienna)       Date:  2003-07       Impact factor: 3.575

10.  Postmenopausal estrogen use affects risk for Parkinson disease.

Authors:  Lillian J Currie; Madaline B Harrison; Joel M Trugman; James P Bennett; G Frederick Wooten
Journal:  Arch Neurol       Date:  2004-06
View more
  2 in total

Review 1.  Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.

Authors:  Valeria De Pasquale; Anna Moles; Luigi Michele Pavone
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

2.  Association Between Dystonia-Related Genetic Loci and Parkinson's Disease in Eastern China.

Authors:  Wen-Yi Yang; Si-Si Jiang; Jia-Li Pu; Chong-Yao Jin; Ting Gao; Ran Zheng; Jun Tian; Bao-Rong Zhang
Journal:  Front Neurol       Date:  2022-02-22       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.